Pfizer (PFE) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7170811035

Pfizer Inc., listed on the New York Stock Exchange under the symbol PFE, is a global leader in the discovery, development, manufacturing, marketing, distribution, and sale of biopharmaceutical products.

The company offers a wide range of medicines and vaccines across various therapeutic areas, including cardiovascular metabolic conditions, migraine, women's health, infectious diseases, and COVID-19 prevention and treatment.

Some of Pfizer's well-known brands include Eliquis, Nurtec ODT/Vydura, Premarin, Prevnar, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, Comirnaty, and Paxlovid.

In addition to its pharmaceutical portfolio, Pfizer is also involved in contract manufacturing, serving wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and more.

Established in 1849 and headquartered in New York, Pfizer has formed collaborative partnerships with leading companies like Bristol-Myers Squibb, Merck KGaA, BioNTech SE, and strategic alliances with CSPC Pharmaceutical Group and Carrick Therapeutics Limited.

For more information about Pfizer Inc., visit their official website at

AI improved, may contain errors or wrong assumptions

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Pfizer (PFE) - Stock Price & Dividends

PFE Stock Overview

Market Cap in USD 157,764m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2012-08-13

PFE Stock Ratings

Fundamental 1.20
Dividend 9.06
Growth 5y -1.11
Rel. Performance vs Sector -5.17
Analysts 3.72
Fair Price Total Ret. 28.09
Fair Price DCF 2.90

PFE Dividends

Yield 12m 6.10%
Yield on Cost 5y 4.93%
Dividends CAGR 5y 21.49%
Payout Consistency 96.4%

PFE Growth Ratios

Growth 12m -29.24%
Growth Correlation 12m -83%
Growth Correlation 3m -40%
CAGR 5y -4.18%
CAGR / Mean Drawdown -0.23
Sharpe Ratio 12m -1.52
Alpha vs SP500 12m -50.42
Beta vs SP500 5y weekly 0.64
CAPM 6.99%
Average Daily Range 2m 2.08%
Regime Oscillator 55.36
Volatility GJR Garch 1y 20.60%
Price / SMA 50 -2.52%
Price / SMA 200 -15.24%
Current Volume 31010.2k
Average Volume 20d 39449k

External Links for PFE Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of PFE stocks?
As of February 29, 2024, the stock is trading at USD 27.04 with a total of 31,010,175 shares traded.
Over the past week, the price has changed by -2.28%, over one month by -1.60%, over three months by -7.55% and over the past year by -30.28%.
Why is PFE stock down?
Check with which Index or Commodity PFE has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return PFE Return S&P 500
1 Month -1.60% 3.05%
3 Months -7.55% 11.73%
12 Months -30.28% 29.22%
What is the forecast for PFE stock price target?
According to ValueRays Forecast Model, PFE Pfizer will be worth about 30.5 in February 2025. The stock is currently trading at 27.04. This means that the stock has a potential upside of +12.94%.
Issuer Forecast Upside
Wallstreet Target Price 32.1 18.9%
Analysts Target Price 38.7 43.0%
ValueRay Target Price 30.5 12.9%

Discover Pfizer Inc: A Comprehensive Overview

History of Pfizer Inc.

Pfizer Inc., established in 1849 by Charles Pfizer and Charles F. Erhart, started as a fine chemicals business. The company's first product was an antiparasitic called santonin. Over the decades, Pfizer transformed into one of the world's premier biopharmaceutical companies. It played significant roles in medical advancements, including mass-producing penicillin during World War II and developing revolutionary drugs like Viagra and Lipitor.

Core Business

At its core, Pfizer is deeply devoted to discovering and producing healthcare solutions that improve life. Its primary focus is on developing medicines and vaccines for a plethora of medical fields, including immunology, oncology, cardiology, endocrinology, and neurology. The company prioritizes innovative research and is known for its robust pipeline of promising new therapies aimed at treating a wide range of diseases.

Side Businesses

Beside its main pharmaceutical products, Pfizer also engages in several side businesses. These include animal health products through its Zoetis division (spun off in 2013), over-the-counter (OTC) consumer health products, and various health-related digital services and platforms. These diversified interests help Pfizer maintain its financial stability and expand its healthcare impact beyond prescription medicines.

Current Market Status

As of 2023, Pfizer Inc. (NYSE: PFE) remains a leader in the pharmaceutical industry. The company has seen significant growth, largely due to the global demand for its COVID-19 vaccine, developed in partnership with BioNTech SE. This has not only boosted Pfizer's revenues but also its position in the market. However, like all companies in the sector, Pfizer faces challenges such as drug patent expirations, regulatory hurdles, and the ongoing need for innovative research and development. Despite these challenges, Pfizer's strong portfolio and pipeline, along with a proactive approach to global health crises, ensure it continues to play a vital role in the healthcare industry.